Gelişmiş Arama

Basit öğe kaydını göster

dc.contributor.authorGörmez S.
dc.contributor.authorErdim R.
dc.contributor.authorErdo?mus O.
dc.contributor.authorCivan M.
dc.contributor.authorÇatako?lu A.B.
dc.contributor.authorGülbaran M.
dc.contributor.authorAytekin V.
dc.date.accessioned2019-08-13T12:10:23Z
dc.date.accessioned2019-08-13T15:53:33Z
dc.date.available2019-08-13T12:10:23Z
dc.date.available2019-08-13T15:53:33Z
dc.date.issued2008
dc.identifier.issn1302-8723
dc.identifier.urihttp://hdl.handle.net/11446/1961
dc.descriptionPubMed ID: 19103539en_US
dc.description.abstractObjective: The purpose of this study was to compare treatment of saphenous vein graft (SVG) lesions with paclitaxel-eluting (PES) and sirolimus-eluting stents (SES) in daily practice with regard to short- and long-term clinical outcomes. Methods: Between August 2002 and September 2006, a total of 71 patients with SVG lesions who were implanted PES or SES with percutaneous coronary intervention in our center were evaluated retrospectively. Forty-six patients with PES (PES group) were compared to twenty-five patients treated with SES (SES group) in terms of in-hospital, 30-day, six-months and 1-year clinical outcomes. Statistical analyses were performed using Chi-Square statistics or Fisher's exact and independent sample t test. Survival analysis was done using Kaplan-Meier method and log-rank test. Results: Baseline clinical characteristics were similar in both groups except for a tendency toward a lower age in the SES group. No statistically significant difference was found between two groups by means of lesion and procedural characteristics. All clinical outcomes at 30-day, 6-month and 1-year after the interventions were similar in both groups. Early stent thrombosis was detected in one patient (2.2%) of PES group (p=0.65). Late stent thrombosis was not observed in both groups. The rate of major adverse cardiac events at 1-year was 8.7% in the PES group and 16% in the SES group (p=0.44). Conclusion: Short- and long-term clinical outcomes of PES and SES in the treatment of SVG lesions are similar. The results of our study showed that both drug-eluting stents are effective and safe in real-world patient with diseased SVGs. © Copyright 2008 by AVES Yay?nc?l?k Ltd.en_US
dc.language.isoengen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAngioplastyen_US
dc.subjectDrug-eluting stentsen_US
dc.subjectOutcomesen_US
dc.subjectSaphenous veinen_US
dc.subjectSurvival analysisen_US
dc.titleTreatment of saphenous vein graft lesions with paclitaxel- and sirolimus-eluting stents: Comparison of short- and long-term clinical outcomesen_US
dc.typearticleen_US
dc.relation.journalAnadolu Kardiyoloji Dergisien_US
dc.departmentDBÜen_US
dc.identifier.issue6en_US
dc.identifier.volume8en_US
dc.identifier.startpage431en_US
dc.identifier.endpage436en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.department-tempDBÜen_US


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster